Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Atomo Diagnostics Ltd. ( (AU:AT1) ) has provided an announcement.
Atomo Diagnostics Limited announced the issuance of 46,929,731 fully paid ordinary shares to new and existing investors at an issue price of $0.0185 per share. This move, executed without disclosure under the Corporations Act, aims to strengthen the company’s financial position and support its operations in the competitive global diagnostic market. The announcement confirms Atomo’s compliance with relevant legal provisions and assures stakeholders of its transparency and adherence to regulatory standards.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Limited is an Australian-headquartered medical device company that provides unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market. The company’s patented devices enhance usability and reliability for rapid point-of-care (POC) and at-home testing, with products commercialized internationally. Atomo has supply agreements for testing applications targeting infectious diseases such as COVID-19, HIV, viral vs bacterial differentiation, and female health.
Average Trading Volume: 458,408
Technical Sentiment Signal: Buy
Current Market Cap: A$12.14M
See more data about AT1 stock on TipRanks’ Stock Analysis page.